Navigation Links
ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting
Date:9/11/2008

MINNEAPOLIS, Sept. 11 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that an unprecedented number of scientific presentations and symposia will focus on ATS Medical products at the upcoming European Association for Cardio-Thoracic Surgeons (EACTS) meeting. The EACTS is a key gathering of cardiovascular surgeons from around the world and is being held in Lisbon, Portugal from September 13-17, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

Professor Thierry Carrel's presentation at the meeting's Techno College on September 13th is entitled "The ATS Enable Valve: Implantation Techniques and Clinical Results". The ATS 3f Enable(R) Aortic Bioprosthesis incorporates the ATS 3f(R) Aortic Bioprosthesis on a Nitinol self-expanding frame which eliminates the need for traditional suturing. Valuable cardiopulmonary bypass and aortic cross clamp time is reduced while providing surgeons and patients with a minimally invasive alternative to traditional open chest procedures. Also at the Techno College, Dr. Mark Slaughter will present "New Surface Treatment of Mechanical Heart Valves", a report on the novel ATS Forcefield(TM) technology which is intended to modify the surface/platelet interaction and adhesion activity with common biomaterials.

The ATS Medical booth exhibition will spotlight several products including the ATS 3f(R) Aortic Bioprosthesis and the new ATS CryoMaze(TM) Clamp. Based on the precept that 'Form Follows Function', the ATS 3f(R) Aortic Bioprosthesis is a revolutionary stentless pericardial aortic tissue valve that operates unlike any other valve. Like a native aortic valve that functions as a tubular structure whose sides collapse in response to pressure, the proprietary tubular valve design of the ATS 3f Aortic Bioprosthesis reproduces the functional characteristics of a native aortic valve, resulting in more normal distribution of stress on the valve leaflets and laminar, non-turbulent trans-prosthetic flow that is indistinguishable from flow across the normal valve. With more than six years of clinical experience to date confirming excellent safety and efficacy, the combination of normal blood flow dynamics and improved stress distribution offered by the ATS 3f Aortic Bioprosthesis provides surgeons and patients a potentially more durable and physiologic solution to aortic valve replacement. The ATS 3f Aortic Bioprosthesis will be the focus of an EACTS Satellite Symposium on September 16th entitled, "The ATS 3f(R) Revolution" that will be moderated by Dr. James Cox, ATS Medical Director.

The ATS CryoMaze Clamp is the only ablation clamp that offers visible transmurality and allows for safe and effective concomitant ablation in coronary artery bypass graft and aortic procedures using a single device and energy source. The entire ATS CryoMaze product line will be the center of discussions at the ATS Medical Symposium on September 15th entitled "Frontiers In Cryoablation Symposium: The Rationale for Lesion Patterns and Cryosurgery." Ablation therapy is expected to be a key growth driver for the company in 2009.

The ATS Open Pivot(R) Mechanical Heart Valves will be highlighted during an in-booth presentation entitled "Anticoagulation of Mechanical Valves and Our ATS Open Pivot Experience" by Professor Guido Van Nooten on Tuesday, September 16th at 10:45 AM.

The ATS Simulus(R) Semi Rigid Annuloplasty Ring, the newest addition to the company's expanding line of mitral valve repair prosthetics, will also be introduced to the European marketplace.

Michael Dale, President and CEO of ATS Medical commented, "Each year we look forward to the EACTS as one of the premier events within the cardiac surgeon community that we serve. This year is particularly exciting. After more than five years of investment and partnerships towards advancing the standard of cardiac surgery, the number of new and genuinely innovative product offerings from ATS in both our heart valve therapies and surgical ablation of cardiac arrhythmias businesses have never been greater. With new clinical updates on our novel Enable sutureless valve, our Forcefield technology, and our Open Pivot mechanical heart valve, we believe that ATS Medical will be of keen interest to many attendees during this year's EACTS meeting."

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 160,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: